Abstract: These results suggested that Konjaku flour (KF) can achieve positive effects on treating obesity, which manifest on reducing BMI, fat mass, blood glucose, and blood lipid, improving hepatic function, and also regulating intestinal microfloral structure. Therefore, changes in gut microbiota may explain in part the effects of KF.
Introduction
Obesity is a complex metabolic disorder frequently associated with gut microbiome dysbiosis. Dietary fiber is a recognized intervention for weight management, yet the clinical efficacy of Konjaku flour (KF)—a traditional Asian food source rich in konjac glucomannan (KGM)—has lacked rigorous human data regarding its specific impact on the microbial ecosystem. This study investigates whether KF acts as a prebiotic to treat obesity and identifies the specific bacterial taxa responsible for observed health benefits.
Methods
Researchers conducted a 5-week, randomized, double-blind, placebo-controlled trial involving 69 obese volunteers (BMI ≥ 28 kg/m²). The intervention group received 10g of KF daily, while the control group received a lotus root starch placebo. Clinical metrics included BMI, fat mass (via DXA scans), and blood parameters (glucose, lipids, liver enzymes). Microbiome analysis was performed using 16S rRNA gene sequencing (V3–V4 region) on the Illumina MiSeq platform, with bioinformatics pipelines (QIIME, RDP classifier) used to assess α-diversity and β-diversity.
Clinical Outcomes
The KF intervention led to significant improvements in physical and metabolic health:
- Weight Loss: The KF group experienced a significant reduction in BMI, dropping from an average of 31.41 to 28.98, alongside a decrease in total fat mass.
- Metabolic Markers: Significant reductions were observed in triglycerides (TG), glycated hemoglobin (HbA1c), and liver enzymes (AST and ALT), indicating improved hepatic function and glycemic control.
Microbiome Remodeling
One of the study's primary findings was the systematic "remodeling" of the gut microbiome. KF treatment notably influenced microbial diversity and community structure.
Diversity and Community Structure
KF treatment significantly altered α-diversity, a hallmark of a healthy and resilient gut ecosystem. While obesity is often linked to reduced microbial richness, the KF group showed distinct shifts in community composition. Principal Coordinate Analysis (PCoA) demonstrated that after 5 weeks, the gut communities of the KF group clustered distinctly away from their baseline state, indicating a systematic shift in the microbial landscape.
Taxonomic Shifts
The study identified several key bacterial players affected by KF:
- Butyrate Producers: KF significantly increased the abundance of Roseburia, Lachnospiraceae, and Intestinimonas. These bacteria produce butyrate, a short-chain fatty acid (SCFA) essential for energy metabolism and anti-inflammatory signaling.
- Reduction of Metabolic Risk Taxa: The treatment reduced the abundance of certain Bacteroides species and Lactococcus, which are often correlated with high-fat diets and metabolic inflammation.
- Lipid Metabolism: A negative correlation was found between Clostridium perfringens and serum total cholesterol, suggesting a potential role for specific strains in lipid regulation.
Conclusion and Limitations
This trial demonstrates that KF supplementation effectively reduces obesity indices and improves metabolic health by modulating the gut microbiota. However, the study's 5-week duration limits insights into long-term sustainability. Additionally, while strong correlations were found, further research (such as fecal microbiota transplants in animal models) is required to establish definitive causality between the microbial shifts and weight loss. Future studies should also directly measure metabolite levels (e.g., SCFAs) to clarify the underlying chemical signaling mechanisms.
Summary updated